Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q3 2022 Earnings Conference Call November 15, 2022 8:00 AM ET Company Participants Alex Lobo – Stern Investor Relations Milton Werner – President and Chief Executive Officer Conference Call Participants Operator Good day, and welcome to Inhibikase Therapeutics' Third Quarter 2022 Financial Results Conference Call. All participants are in listen-only mode. [Operator Instructions] Please note, this event is being recorded. I would now turn the conference over to Alex ...

Pipeline and Programs - Inhibikase Therapeutics is developing a multi-therapeutic pipeline of kinase inhibitor therapeutics focused on neurodegeneration, oncology, and infectious diseases[3] - IkT-148009, a lead c-Abl inhibitor program, is in Phase 2a study for Parkinson's disease (PD) and related disorders[4] - IkT-001Pro, an oncology product, is a BCR-Abl inhibitor with a potentially improved safety profile for leukemias and gastrointestinal cancers, with an IND application submitted for Chronic Myeloid Leukemia[5] - The company has a robust patent portfolio with protection to 2033 for oncology and 2036 for neurodegeneration[5] Financial Highlights - The company received $20.8 million in peer-reviewed grants and contracts from NIH, DoD, the Michael J Fox Foundation, and the Georgia Research Alliance[6] - Inhibikase Therapeutics secured $63 million in gross proceeds from investor capital in 2021[6] - As of June 30, 2022, the company's total working capital was $29,773,286[41] - As of June 30, 2022, the company's cash holdings were $32,212,276[43] Market and Clinical Data - The U S Parkinson's disease market is large, with an estimated 930,000 to 1,200,000 patients[11] - By 2025, Parkinson's disease drug sales are expected to exceed $6 billion[11] - Phase 1 trial data for IkT-148009 showed dose-proportional clinical pharmacokinetics and no clinically significant adverse events in healthy subjects (N=88) and Parkinson's patients (N=13)[24] - In CML, Gleevec® and its generics have $330.5 million in net U S sales, with generic Gleevec® holding over 57% market share[33]

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q2 2022 Earnings Conference Call August 15, 2022 8:00 AM ET CompanyParticipants Milton Werner - CEO Joseph Frattaroli - CFO Alex Lobo - Stern IR Conference Call Participants Danya Ben-Hail - JonesTrading Operator Good day, and welcome to Inhibikase Therapeutics’ Second Quarter 2022 Financial Results Conference Call. All participants are in listen-only mode. [Operator Instructions] Please note, this event is being recorded. I would now turn the conference over to Al ...

3Q 2022 | BUSINESS PRESENTATION Clinical Development of Disease-Modifying Therapeutics for Neurodegenerative Disease & Cancer Inhibikase.com : IKT DISCLAIMER This presentation shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This pre ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) ( State or other jurisdiction of incorp ...

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q1 2022 Earnings Conference Call May 17, 2022 8:00 AM ET Company Participants Alex Lobo - Stern Investor Relations Milton Werner - Chief Executive Officer Joseph Frattaroli - Chief Financial Officer Conference Call Participants Operator Greetings, welcome to Inhibikase Therapeutics’ First Quarter 2022 Financial Results Conference Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. [Operato ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) ( State or other jurisdiction of incor ...

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2021 Results Conference Call April 1, 2022 8:00 AM ET Company Participants Alexander Lobo - Stern Investor Relations Dr. Milton Werner - Chief Executive Officer Joseph Frattaroli - Chief Financial Officer Operator Greetings, welcome to Inhibikase Therapeutics’ Fourth Quarter Full Year 2021 Financial Results. At this time, all participants are in listen only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please n ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 26-3407249 (State or other juris ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39676 INHIBIKASE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) ( State or other jurisdiction of i ...